GlassScriptPhysician profile
Jennifer A Totten
NPI 1497940605
$6,729.32
in general payments reported to CMS, 2019-2025
31 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $733 · 2021: $895 · 2022: $1,232 · 2023: $863 · 2024: $1,418 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $44.73 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.39 |
| Education | $44.73 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,043.38 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Pfizer INC. | $745.55 | 2019-2025 | |
| Janssen Biotech, INC. | $729.26 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.65 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $551.13 | 2019-2025 | Entyvio |
| Celgene Corporation | $321.45 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $175.46 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $171.80 | 2020-2022 | |
| Qol Medical, LLC | $155.44 | 2019-2023 | Sucraid |
| Ardelyx, INC. | $145.59 | 2022-2023 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $118.98 | 2022 | |
| Braintree Laboratories, INC. | $116.50 | 2020-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $114.70 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $94.33 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $88.09 | 2019-2024 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $62.64 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $57.33 | 2023-2024 | Rebyota |
| Genzyme Corporation | $50.55 | 2022-2024 | |
| Ucb, INC. | $48.70 | 2019 | |
| Organon LLC | $47.11 | 2023-2024 | Renflexis, Hadlima |
| Allergan, INC. | $43.46 | 2019 | |
| Celltrion USA INC. | $34.25 | 2024 | Zymfentra |
| Boston Scientific Corporation | $26.72 | 2019 | |
| Amgen INC. | $21.75 | 2022 | |
| Lilly USA, LLC | $20.32 | 2024 | Omvoh |
| Concordia Pharmaceuticals INC. | $19.38 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.72 | 2021 | |
| Vivus LLC | $15.79 | 2023 | Qsymia |
| Daiichi Sankyo INC. | $13.25 | 2019 | |
| Alfasigma USA, INC. | $12.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Totten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.